Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma nears FDA milestone in cancer trial - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shared that over 75% of the 90 patients in the proof-of-concept trial have been randomized, with full enrollment expected by the end of the year.
Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines
Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperature. The two companies plan to combine HelixNano's technology, which uses messenger ribonucleic acid (mRNA) to instruct the immune system how to fight off infectious diseases, with Medicus's method of delivering vaccines using dissolvable microneedle patches.
Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma (BCC) of the skin. The company is seeking a meeting during the week of October 6, aiming to gain the agency's approval to fast-track the program and seek feedback on future clinical plans.
Medicus Pharma expands pipeline with Antev acquisition - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest strategic developments. Bokhari discussed the definitive agreement to acquire Antev, a UK-based company advancing clinical programs for two indications.
Medicus to acquire UK biotech Antev in share deal worth up to $65m
Medicus Pharma (NASDAQ:MDCX) has agreed to acquire Antev, a UK-based drug developer working on treatments for prostate conditions, in a share-based deal that could be worth up to US$65 million in future milestone payments. Under the terms of the agreement, Antev shareholders will receive 2.67 million Medicus shares, equivalent to around 17% of the enlarged company, and worth $7.7 million at current prices.
Medicus Pharma targets horse cancer with new trial – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a veterinary clinical development program to the FDA targeting squamous cell carcinoma in horses. The move follows the company's receipt of an orphan drug designation for the condition from the veterinary division of the agency.
Medicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horses
Medicus Pharma (NASDAQ:MDCX) said on Monday it has submitted a comprehensive product development plan to the US Food and Drug Administration (FDA) to advance its investigational treatment for external squamous cell carcinoma (SCC) in horses. The plan was submitted under the company's existing Investigational New Animal Drug file and follows the FDA's Minor Use in Major Species designation, which Medicus received in December 2024 for its dissolvable Doxorubicin-containing microneedle array (D-MNA).
Medicus Pharma appoints KPMG as new auditor, expands global clinical programs
Medicus Pharma (NASDAQ:MDCX) said it has appointed KPMG as its independent registered public accounting firm for the 2025 fiscal year, replacing EisnerAmper following a review process led by the company's audit committee and approved by its board. The transition, announced on June 4, comes as the clinical-stage biotech company ramps up its global operations and research programs.
Medicus Pharma unveils pricing of $7M public offering
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its $7 million public offering of 2.26 million shares on a “best-efforts” basis at $3.10 per unit. Each unit includes one share and one warrant to purchase a share at an exercise price of $3.10, with the warrants expiring five years from the date of issuance and not trading on any securities exchange.
Medicus Pharma begins UAE cancer trial expansion – ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's newly announced regulatory approval to expand its Phase 2 trial into the United Arab Emirates. The study is focused on a noninvasive therapy for basal cell carcinoma (BCC), the most common form of cancer globally.
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer. Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.
